We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01911039
Recruitment Status : Unknown
Verified March 2015 by Laura Johnston, Stanford University.
Recruitment status was:  Recruiting
First Posted : July 30, 2013
Last Update Posted : April 1, 2015
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Laura Johnston, Stanford University

Brief Summary:
Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or hematopoietic cell transplant from another person (allogeneic transplant). This study will determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor regulatory T cells and whether their cGVHD responds to the infusion.

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Allogeneic Hematopoietic Cell Transplant Recipient Biological: Regulatory T Cells Phase 1

Detailed Description:


Determine the safety and tolerability of donor T regulatory (Treg) cell infusions in subjects with steroid dependent/refractory chronic graft versus host disease.


  1. Determine the quantitative blood Treg cell changes following the cell infusions
  2. Determine clinical efficacy of donor Treg cells as failure-free survival (FFS) defined by the absence of a new immunosuppressive therapy added, non-relapse mortality, and recurrent malignancy at Day 180 after the first Treg infusion
  3. In addition to FFS, the study will measure the change in:

    1. cGVHD symptom burden measured by the Lee cGVHD Symptom Scale by increase in >7 points
    2. NIH organ-specific cGVHD scale
    3. The reduction in daily corticosteroid requirement of prednisone to <=0.25 mg/kg-day at Day 180 after the first Treg infusion

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Study Start Date : July 2013
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : July 2016

Arm Intervention/treatment
Experimental: Regulatory T Cells
Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
Biological: Regulatory T Cells
Other Name: donor Treg cell

Primary Outcome Measures :
  1. The frequency of adverse events related to the donor Treg infusions (e.g., grade III-IV aGVHD by the modified Keystone criteria and grade 3 or higher infusional toxicities graded according to the CTCAE v. 4) [ Time Frame: Up to day 180 ]
    For infusion-related toxicities, recipients will be monitored for 1 hour after the Treg infusion. Additional toxicities which may occur during the first 28 days after the Treg infusions will count towards the assessment of safety and tolerability (DLT assessment) (e.g., development of aGVHD). Acute GVHD will be assessed using the modified Keystone criteria on Days 14, 28, 42, 56, 84 and 180 after the Treg infusion (or if the subject is exhibiting signs of aGVHD in-between study visits). Dose limiting toxicities are defined in Section 8. Only toxicities which occur during the first 28 days after the cell infusion will count towards the assessment of DLTs. A dose of Treg will be considered safe if DLTs occur in only 1/6 or 0/3 members of the cohort during the dose-escalation phase.

Secondary Outcome Measures :
  1. Change in absolute blood Treg levels [ Time Frame: Baseline to day 42 ]
    The change in Treg cell counts from baseline to post infusion will be depicted in boxplots of both relative proportion and absolute numbers. Mean log (fold change) and confidence intervals will be calculated.

  2. Improvement in Failure Free Survival (FFS) over cGVHD [ Time Frame: At day 180 ]
    FFS is defined as the absence of a third line therapy (treatment failure). Estimated by the Kaplan-Meier product-limit method, with standard confidence limits.

  3. Successful achievement of cGVHD partial response or Complete response by the NIH consensus criteria [ Time Frame: Up to day 180 ]
    1. Complete Response (CR) - Complete resolution of all reversible manifestations of cGVHD. Irreversible manifestations will be defined as (NIH consensus criteria) are: ocular xerosis, esophageal stricture, and bronchiolitis obliterans.
    2. Partial Response (PR) - At least a 25% absolute or 50% relative change (whichever is greater) when comparing start and end measurements in one cGVHD manifestation without worsening in the other manifestations.

    The results will be summarized in tabular form, with confidence intervals for the trinomial proportions.

  4. The ability to reduce steroid requirements to <0.25 mg/kg-day [ Time Frame: At day 180 ]
  5. Change in >7 points on the Lee cGVHD Symptom scale relates to improvement in quality of life [ Time Frame: Baseline to day 180 ]
    A one-sample t-test will be used on the change in scale from baseline to months 1, 3, and 6.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Steroid dependent/refractory cGVHD defined as:

    • Steroid dependent disease: Persistent cGVHD manifestations requiring a glucocorticoid dose >= prednisone 0.25 mg/kg/day (0.5 mg/kg orally [po] every other day) for at least 12 weeks
    • Steroid refractory disease: Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednisone 0.5 mg/kg/day (1 mg/kg po every other day) for at least 4 weeks
  • Participants must be receiving systemic glucocorticoid therapy for cGVHD; all immunosuppressive therapy may include but not be limited to tacrolimus, sirolimus, CellCept, cyclosporine, and systemic corticosteroid must be at stable doses for 28 days prior to the first cell infusion
  • Chronic GVHD manifestations that can be followed on physical or laboratory exam; these include but are not necessarily limited to:

    • Skin changes
    • Oral mucosa changes
    • Bronchiolitis obliterans
    • Ocular changes
  • Karnofsky performance status >= 60
  • Serum creatinine =< 2 mg/dL
  • Absolute neutrophil count (ANC) > 1 x 10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 20 x upper limit of normal (ULN) or
  • Total bilirubin =< 10 x ULN
  • Allogeneic hematopoietic cell transplant recipient
  • Transfusion independent
  • Oxygen saturation during exertion is maintained at >= 88% on room air
  • Does not have clinically significant, symptomatic uncontrolled heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
  • DONOR: Age >= 18 to =< 75 years old
  • DONOR: Karnofsky performance status of >= 70% defined by institutional standards
  • DONOR: Must be the same sibling donor from whom the recipient's blood and marrow graft was collected for the original allogeneic transplant that is human leukocyte antigen (HLA) 7/8 or 8/8 matched at the HLA-A, B,C, DRB1
  • DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-lymphotropic virus type I (HTLV 1) and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction positive (PCR+), or hepatitis C Ab or PCR+, Syphilis (Treponema) screen and HIV 1 and hepatitis C by nucleic acid testing (NAT) have been collected prior to apheresis
  • DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis
  • DONOR: Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate
  • DONOR: Donor selection will be in compliance with 21 Code of Federal Regulations (CFR) 1271

Exclusion Criteria:

  • Original transplant utilized an unrelated donor graft
  • Uncontrolled infections that are not responsive to antimicrobial therapy
  • Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy
  • Second malignancy except for skin cancer within the last 5 years
  • Received any investigational agent =< 28 days before Treg infusions
  • Received filgrastim (GCSF) treatment within one month of enrollment
  • Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within 3 months of enrollment
  • DONOR: Evidence of active infection or viral hepatitis
  • DONOR: HIV positive
  • DONOR: Pregnant donor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01911039

Contact: Joanne M Otani, RN, MSN, PHN 650-721-2372 joanne.otani@stanford.edu

United States, California
Stanford University Recruiting
Palo Alto, California, United States, 94305
Contact: Joanne Otani, RN, MSN, PHN    650-721-2372    joanne.otani@stanford.edu   
Principal Investigator: Laura J Johnston, MD         
Sub-Investigator: Sally Arai, MD, PhD         
Sub-Investigator: Ginna Laport, MD         
Sub-Investigator: Robert Lowsky, MD         
Sub-Investigator: Everett Meyer, MD, PhD         
Sub-Investigator: Joanne Otani, RN, MSN, PHN         
Sub-Investigator: Kevin Sheehan, PhD         
Sub-Investigator: Judith Shizuru, MD, PhD         
Sub-Investigator: Wen Kai Weng, MD, PhD         
Sponsors and Collaborators
Laura Johnston
National Institutes of Health (NIH)

Responsible Party: Laura Johnston, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT01911039     History of Changes
Other Study ID Numbers: BMT253
First Posted: July 30, 2013    Key Record Dates
Last Update Posted: April 1, 2015
Last Verified: March 2015

Keywords provided by Laura Johnston, Stanford University:

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases